VETOQUINOL Corporate brochure 2011 (year 2010)

In 2010, more than 10,000 tonnes of products were manufactured in different pharmaceutical forms (sterile injectable liquids, oral liquids, powders and granules, pastes and creams, tablets and medicated premixes). The Production sites, complying with Good Manufacturing Practice, are specialised by pharmaceutical form and geographic area. With a view to optimising responsiveness and logistics costs, they primarily serve the markets located within their continent on a priority basis, but are also capable of supplying the rest of the world. In India, the products developed by the new Vétoquinol subsidiary are manufactured by local partner subcontractors. LURE (FRANCE) : The Group’s principle production site capable of producing large quantities. 240 employees, 10 million units sold per year, geared towards the global market. Specialties: injectables, tablets, liquids, creams and powders. TARARE (FRANCE) : 20 employees specialising in non-medicinal products. Serves all markets, including the U.S.A., for non-pharmaceutical products such as Ipakitine ® . GORZÓW (POLAND) : Two plants that manufacture veterinary medicinal products and non-medicinal products (injectables, tablets, liquids, powders, granules and liquid insecticides) intended for all European markets and overseas export markets. PRINCEVILLE (CANADA) : Food and Drug Administration (FDA) approved plant, dedicated to veterinary medicinal products and non-medicinal products for North America. A special building is dedicated to penicillins. This site primarily serves Canada and the U.S.A. FORLI (ITALY) : The site manufactures veterinary medicinal products and non-medicinal products for the domestic market but also for export (essentially North Africa, Europe and Central Asia). These are mainly pre-mixtures in the form of powders, granules and liquids, and are exclusively meant to be used in treating livestock. 26 Industrial Production A High Performance Industrial Model Vétoquinol has five production sites, which produced in aggregate nearly 25 million boxes in 2010, in strict compliance with increasingly demanding, pharmaceutical standard similar to those for human pharmaceuticals use.